CardioExchange Archive

November 12th, 2012

Selections from Richard Lehman’s Literature Review: November 12th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include multivitamins for the prevention of CVD in men, the TRILOGY ACS trial, statin use and reduced cancer mortality, and more.

---

October 22nd, 2012

NIH Trial of Lifestyle Intervention for Type 2 Diabetes Stopped for Futility After 11 Years

Larry Husten, PHD

The NIH today announced the early termination of a large randomized trial testing a lifestyle intervention approach to weight loss in type 2 diabetics. More than 5,000 patients with type 2 diabetes were randomized to participate in an intensive lifestyle intervention program or a traditional program of diabetes support and education in Look AHEAD (Action for Health […]

---

October 4th, 2012

U.K. Study Casts Doubts on Value of Type 2 Diabetes Screening

Larry Husten, PHD

The dramatic growth in type 2 diabetes has resulted in increased interest in screening programs. Now a new study published in the Lancet raises concerns that screening programs may not result in long-term improvement in outcomes. In the ADDITION-Cambridge study, investigators in the U.K. randomized general practices to either screening or no screening.  The practices allocated to screening were […]

---

October 1st, 2012

Selections from Richard Lehman’s Literature Review: October 1st

Richard Lehman, BM, BCh, MRCGP

This week’s topics include exercise and mortality in those with diabetes, BP targets in those with type-2 diabetes, and the diagnostic accuracy of FFR from CT angiography.

---

September 17th, 2012

Selections from Richard Lehman’s Literature Review: September 17th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include surgical vs. lifestyle treatment for type-2 diabetes, omega-3 fatty-acid supplementation and the risk for major CVD events, FAME 2, using high-sensitivity cardiac troponin T for one-hour rule-out or rule-in of acute MI, and the timing of acute MI in patients having total hip or knee replacement.

---

August 13th, 2012

Selections from Richard Lehman’s Literature Review: August 13th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include using existing data for new research; normal weight, diabetes, and non-CVD death; cholesterol levels in U.S. kids; statins and diabetes; HDL-C and MI protection; statin treatment; hypertension treatment; clopidogrel and PPIs; and an analysis behind the “innovation crisis” of the pharmaceutical industry.

---

August 8th, 2012

Selections from Richard Lehman’s Literature Review: August 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include heart failure and depression, endoscopic vs. open vein-graft harvest for CABG, linagliptin vs. glimepiride in those with type-2 diabetes, weight gain with smoking cessation, ACE inhibitors and pneumonia risk, and the effect of speech therapy after stroke.

---

April 2nd, 2012

Selections from Richard Lehman’s Literature Review: Week of April 2nd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include cardiovascular risk among U.S. adults and statin-treated patients, mobility in those with type-2 diabetes, the causal association between IL6R-related pathways and CVD, and promoting exercise.

---

June 21st, 2011

Meta-Analysis Examines Risk of Diabetes Associated with Statins

Larry Husten, PHD

Although the cardiovascular benefits of statin therapy are well-characterized, recent studies have raised concerns that intensive statin therapy increases the risk for developing type 2 diabetes. Now, a new meta-analysis published in JAMA provides a more precise estimate of the risk for diabetes associated with statin therapy and also weighs that risk against the cardiovascular […]

---

May 2nd, 2011

FDA Approves New Drug for Type 2 Diabetes

Larry Husten, PHD

The FDA announced today that it has approved linagliptin, a new drug for type 2 diabetes. The DPP-4 inhibitor was developed by Eli Lilly and Boehringer Ingelheim and will be sold under the brand name of Tradjenta. Linagliptin was studied in 3,800 patients with type 2 diabetes, the FDA said, and was better than placebo in […]

---